BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

Cell

Volumn 66, Issue 1, 1991, Pages 161-171

  Pendergast, Ann Marie ^a   Muller, Alexander J ^a   Havlik, Marie H ^a   Maru, Yoshiro ^a   Witte, Owen N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; LEUKEMIA; ONCOGENE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMAL; BINDING SITES; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EXONS; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMAN; INSECTS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS; ONCOGENES; PHOSPHOTYROSINE; PLASMIDS; REGULATORY SEQUENCES, NUCLEIC ACID; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSLATION, GENETIC; TYROSINE; VARIATION (GENETICS);

EID: 0025766195     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/0092-8674(91)90148-R     Document Type: Article

References (55)

1. Binding of SH2 domains of phospholipase Cγ1, GAP, and src to activated growth factor receptors
2. P210 BCR/ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells
3. Oncogenes and signal transduction
4. 1-positive acute lymphocytic leukemia (ALL)
5. bcr/abl gene of the Philadelphia chromosome
6. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
7. Tyrosine phosporylation of GAP and GAP-associated proteins in lymphoid and fibroblast cells expressing lck
8. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of P13-kinase to the PDGF β-receptor
9. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia
10. Nucleotide sequence analysis of human abl and bcr-abl cDNAs
11. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential
12. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
13. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
14. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
15. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
16. Protein kinase recognition sequence motifs
17. The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function
18. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins
19. Only site directed antibodies reactive with the highly conserved src homologous region of the v-abl protein neutralize kinase activity
20. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
21. Transforming and membrane proteins
22. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc
23. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
24. Cross-linking of T-cell surface molecules CD4 and CD8 stimulates phosphorylation of the lck tyrosine protein at the autophosphorylation site
25. The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-γ
26. gag-crk, to a broad range of phosphotyrosine-containing proteins
27. Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins
28. A novel viral oncogene with structural similarity to phospholipase C
29. The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity
30. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
31. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
32. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins
33. c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome
34. Src homology region 2 domains direct protein-protein interactions in signal transduction
35. ras GTPase-activating protein
36. BCR first exon sequences specifically activate BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
37. Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation
38. c-src complexes, and P13-kinase
39. Non-catalytic domains of cytoplasmic protein-tyrosine kinases: regulatory elements in signal transduction
40. Role of the ABL oncogene tyrosine kinase activity in human leukaemia
41. Baculovirus expression of functional P210 BCR-ABL oncogene product
42. Evidence for regulation of the cABL tyrosine kinase by a cellular inhibitor
43. Biochemical characterization of baculovirus-expressed rap 1A/K rev-1 and its regulation by GTPase-activating proteins
44. Similarity in membrane proteins
45. The viral and cellular forms of the Abelson (abl) oncogene
46. Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation
47. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
48. Cloning of P13 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases
49. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase
50. Sequence similarity of phospholipase C with the non-catalytic region of src
51. Structural characterization of the BCR gene product
52. Molecular cloning of two types of GAP complementary DNA from human placenta
53. Cloning of bovine GAP and its interaction with oncogenic ras p21
54. Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures